|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **eTable 2** Partial correlations between loge sNfL concentrations and immune cell subpopulations frequencies in subgroups of patients at baseline | | | | | |
|  | **RRMS no treatment (n=23)** | **RRMS active treatment (n=100)** | **RRMS highly active treatment (n=55)** | **PMS no treatment (n=29)** | **PMS active and highly active treatment (n=15)** |
|  | **rp/p** | **rp/p** | **rp/p** | **rp/p** | **rp/p** |
| Total CD3+ | (-)0.077/0.741 | 0.112/0.274 | (-)0.031/0.825 | (-)0.332/0.091 | (-)0.484/0.094 |
| CD3+CD4+ | (-)0.017/0.943 | **0.201/0.047** | 0.073/0.602 | 0.006/0.977 | (-)0.402/0.174 |
| CD3+CD4+CD25+CD127- (CD4+T-reg) | 0.190/0.408 | 0.049/0.632 | 0.018/0.897 | (-)0.190/0.342 | (-)0.156/0.610 |
| CD3+CD8+ | (-)0.121/0.602 | (-)0.097/0.343 | (-)0.146/0.296 | (-)0.348/0.075 | (-)0.179/0.558 |
| CD3+CD8+CD28-CD127- (CD8+T-reg) | 0.032/0.891 | (-)0.123/0.229 | (-)0.042/0.763 | (-)0.021/0.916 | (-)0.083/0.787 |
| CD3+CD4+CCR6-CD161-CXCR3+ (Th1) | 0.183/0.427 | (-)0.022/0.826 | **0.276/0.045** | 0.100/0.620 | (-)0.252/0.407 |
| CD3+CD4+CCR6+CD161+CXCR3-CCR4+ (Th17) | (-)0.148/0.521 | (-)0.004/0.965 | 0.143/0.307 | 0.123/0.541 | 0.368/0.215 |
| CD3+CD4+CCR6+CD161+CxCR3highCCR4low (Th1/Th17) | 0.298/0.190 | 0.045/0.658 | (-)0.056/0.690 | 0.124/0.538 | (-)0.460/0.114 |
| Total CD19+ | (-)0.241/0.293 | 0.004/0.972 | (-)0.087/0.537 | 0.345/0.078 | 0.534/0.060 |
| CD19+CD24highCD38low (B-memory) | 0.032/0.891 | (-)0.103/0.311 | (-)0.028/0.840 | (-)0.217/0.276 | 0.329/0.273 |
| CD19+CD24lowCD38low (B-mature) | 0.116/0.616 | 0.052/0.611 | 0.065/0.642 | (-)0.11/0.957 | 0.236/0.437 |
| CD19+CD24highCD38high (B-reg) | 0.170/0.461 | (-)0.130/0.200 | 0.085/0.546 | **(-)0.431/0.025** | (-)0.271/0.370 |
| CD19+CD24-CD38high (plasma B-cells) | 0.134/0.563 | 0.055/0.592 | (-)0.119/0.397 | (-)0.019/0.925 | **(-)0.643/0.018** |
| CD16+CD56low (CD56dim NK cells) | 0.250/0.275 | (-)0.116/0.256 | 0.206/0.139 | (-)0.080/0.692 | 0.124/0.686 |
| CD16+CD56high (CD56bright NK cells) | (-)0.408/0.066 | (-)0.026/0.800 | (-)0.202/0.146 | 0.070/0.727 | 0.303/0.314 |
| Abbreviations: RRMS = relapsing remitting MS; PMS = progressive multiple sclerosis; active treatment= interferon, glatiramer acetate, teriflunomide and dimethyl fumarate; highly active treatment = fingolimod, natalizumab, alemtuzumab, rituximab and ocrelizumab. sNfL= serum neurofilament light chain; rp = partial correlation coefficient; The rp’es are corrected for age and gender. Significant p-values are shown in bold together with the corresponding rp. None of the p-values survived multiple testing. | | | | | |